Repligen Corporation Prices Public Offering of Shares of Common Stock
June 27 2017 - 7:05PM
Repligen Corporation (NASDAQ:RGEN) today announced the pricing of
an underwritten public offering of 2,807,017 shares of its common
stock at a public offering price of $42.75 per share. In addition,
Repligen Corporation has granted the underwriters a 30-day option
to purchase up to an additional 421,052 shares of its common
stock at the public offering price, less underwriting discounts and
commissions. Repligen expects proceeds from the offering, before
deducting underwriting discounts and commissions and other offering
expenses, to be approximately $120 million, excluding any exercise
of the underwriters’ option to purchase additional shares. The
offering is expected to close on or about July 3, 2017, subject to
customary closing conditions.
J.P. Morgan Securities LLC and Stephens Inc. are
acting as joint book-running managers for the offering. Janney
Montgomery Scott LLC is acting as lead co-manager for the offering
and Craig-Hallum Capital Group LLC is acting as a co-manager for
the offering.
These securities will be issued and sold pursuant
to an automatically effective shelf registration statement
(including a base prospectus) that was previously filed with the
Securities and Exchange Commission (“SEC”). A preliminary
prospectus supplement relating to this offering has been filed with
the SEC. Copies of the final prospectus supplement and the
accompanying prospectus relating to this offering, when available,
may be obtained from J.P. Morgan Securities LLC, Attention:
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com and from Stephens Inc., ATTN: Equity
Syndicate Desk, 111 Center Street, Little Rock, AR 72201, or by
telephone at (800) 643-9691, or by email at
prospectus@stephens.com.
This press release shall not constitute an offer to
sell or a solicitation of an offer to buy, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a
bioprocessing company focused on the development, manufacture and
commercialization of highly innovative products used to manufacture
biologic drugs. Our bioprocessing products are sold to major life
sciences companies, biopharmaceutical development companies and
contract manufacturing organizations worldwide. We are the leading
manufacturer of Protein A affinity ligands, a critical component of
Protein A resins that are used to separate and purify monoclonal
antibody-based therapeutics. In upstream processes, our XCell™ ATF
systems and growth factors are used to accelerate and increase
productivity during the cell culture stage of biologic drug
manufacturing. In downstream processes, we developed and market our
innovative line of OPUS® chromatography columns that we deliver
pre-packed with our customers’ choice of resin for their
bench-scale through clinical production-scale purification needs.
With the acquisition of TangenX, we also manufacture single-use
Sius™ TFF cassettes and hardware, used in downstream protein
concentration and filtration processes. Repligen’s corporate
headquarters are in Waltham, MA (USA) and our manufacturing
facilities are located in Waltham, MA, Shrewsbury, MA, Lund, Sweden
and Weingarten, Germany.
Cautionary Language Concerning
Forward-Looking Statements
This press release contains forward-looking
statements regarding our future business expectations, which are
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that
statements in this press release which are not strictly historical
statements, constitute forward-looking statements, including,
without limitation, statements regarding completion of the proposed
offering and the anticipated use of proceeds of the proposed
offering, constitute forward-looking statements identified by words
like “believe,” “expect,” “may,” “will,” “should,” “seek,”
“anticipate,” or “could” and similar expressions. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including, without limitation,
uncertainties related to market conditions and the completion of
the public offering on the anticipated terms or at all. These and
other risks and uncertainties are described in greater detail in
the section entitled "Risk Factors" in the prospectus for this
offering, Repligen’s most recent Annual Report on Form 10-K on file
with the Securities and Exchange Commission and the other reports
that Repligen periodically files with the Securities and Exchange
Commission. Actual results may differ materially from those
Repligen contemplated by these forward-looking statements. These
forward looking statements reflect management’s current views and
Repligen does not undertake to update any of these forward-looking
statements to reflect a change in its views or events or
circumstances that occur after the date hereof except as required
by law.
Source:
Repligen Corporation
Sondra Newman
Senior Director Investor Relations
(781) 419-1881
snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024